Core Viewpoint - The article emphasizes the significance of cell biology research in various biomedical fields, including tissue barrier functions, receptor signaling networks, enzyme inhibition studies, amyloid protein research, and the future of medical revolutions [3]. Group 1: Global Hot Topics - Topic 1: Nanomedicine in Metabolic Disorders focuses on innovative nanotechnology-based approaches for diagnosing and treating metabolic diseases, highlighting advancements in targeted drug delivery systems, nano-diagnostic platforms, and integrated therapeutic systems [4]. - Topic 2: Stem Cells and 3D Cellular Models discusses the transformative impact of stem cells and tissue engineering, particularly in conjunction with 3D models and nanotechnology, on biomedical research objectives [7]. Group 2: Submission Deadlines and Journals - Submission deadline for Topic 1 is March 31, 2026, and it is associated with the journal "Artificial Cells, Nanomedicine, and Biotechnology" [5]. - Submission deadline for Topic 2 is May 31, 2026, also linked to the journal "Artificial Cells, Nanomedicine, and Biotechnology" [7]. Group 3: High-Impact Journals - The journal "Amyloid" has an impact factor of 7.4 and focuses on amyloid proteins and related diseases, covering various aspects such as etiology, epidemiology, and clinical research [11]. - The "Journal of Enzyme Inhibition and Medicinal Chemistry" has an impact factor of 5.4, concentrating on enzyme inhibitors and their role in drug development [15]. - The journal "Artificial Cells, Nanomedicine, and Biotechnology" has an impact factor of 4.5, emphasizing interdisciplinary research in artificial cells and nanomedicine [20].

Group 1 - Stroke has a high incidence and disability rate, making it a leading health threat, despite advancements in acute vascular recanalization techniques [1] - Many stroke patients suffer from severe neurological deficits, leading to long rehabilitation processes and significant burdens on families and society [1] - Regenerative medicine, particularly stem cell therapy, offers new hope for addressing the global challenge of nerve repair [1] Group 2 - A live session featuring Dr. Huo Xiaochuan, a neurosurgeon from Capital Medical University, and Li Li, founder and chairman of Senpuri (Beijing) Cell Technology Co., will discuss the scientific principles, clinical evidence, safety boundaries, and future prospects of stem cell therapy [1] - Dr. Huo Xiaochuan is recognized for his contributions to stroke intervention and has received the Wang Zhongcheng Annual Young Physician Award [1]

Core Insights - A new three-dimensional organoid named "Budoid" has been developed by a team at the Swiss Federal Institute of Technology in Lausanne, showcasing key features of limb development, including symmetry breaking and early cartilage formation [1][2] Group 1: Research and Development - The research published in the latest issue of "Science Advances" highlights the role of chemical signaling between different cell types during early embryonic development, particularly in limb formation [1] - The study addresses the challenges of researching the short-lived Apical Ectodermal Ridge (AER) cells, which guide the growth of underlying cells to form bones, cartilage, and connective tissues [1] - The team cultivated a mixed cell population from mouse embryonic stem cells that naturally formed AER, surface ectoderm, and mesoderm cells, covering all major cell types involved in limb development [1] Group 2: Applications and Implications - "Budoid" provides a novel practical system for exploring difficult areas in embryonic development, such as how cells coordinate behavior, how early structures develop, and how cartilage forms [2] - The potential applications of this research extend beyond basic studies to congenital disease modeling, testing chemicals that may impair limb development, and even promoting regenerative medicine applications [2]

Core Insights - The research team from the Swiss Federal Institute of Technology in Lausanne has developed a new three-dimensional organoid called "Budoid," which exhibits key features of developing limbs, including symmetry breaking and early cartilage formation [1][2] Group 1: Research and Development - The study published in the journal "Science Advances" highlights the importance of chemical signaling between different cell types during the early stages of embryonic development, particularly in limb formation [1] - Previous organoid models focused mainly on mesodermal cells, neglecting the role of the Apical Ectodermal Ridge (AER) and other ectodermal cells in guiding limb formation [2] - The "Budoid" was created using mixed cell populations derived from mouse embryonic stem cells, which naturally formed structures resembling AER, superficial ectoderm, and mesoderm cells, covering all major cell types involved in limb development [2] Group 2: Applications and Implications - "Budoid" provides a novel platform for exploring difficult-to-study areas in embryonic development, such as how cells coordinate behavior, how early structures develop, and how cartilage forms [2] - The implications of this research extend beyond basic science, potentially aiding in congenital disease modeling, testing chemicals that may impair limb development, and advancing regenerative medicine applications [2] - The new stem cell-based approach offers a more ethical alternative to traditional animal experiments in biomedical research, allowing for the reproduction of key embryonic tissue features without the need for large numbers of embryos [3]

Financial Data and Key Metrics Changes - The company ended Q1 with a negative growth of 1%, but when excluding two large cell therapy customers, the growth for the rest of the business was approximately 1% [6][8] - The company anticipates a similar overall growth rate for Q2, projecting a negative growth of 1% again, but with an adjusted growth of 3% when excluding the impact of the two customers [25][96] Business Line Data and Key Metrics Changes - The diagnostics business grew mid-single digits in Q1, building on a mid-teen growth from the previous year, indicating strong performance despite market challenges [30] - The ProteinSimple franchise has consistently outperformed, with no down quarters and double-digit growth in many recent quarters, indicating its resilience in a tough market [26][68] - The Spatial Biology segment saw flat revenue in Q1, but bookings increased double-digit, suggesting a positive trend moving forward [27][74] Market Data and Key Metrics Changes - The pharmaceutical market, which constitutes 30% of the company's revenue, has shown recovery with double-digit growth in recent quarters, alleviating previous concerns about regulatory impacts [11][12] - Academic market performance has improved, with expectations of a flat NIH budget, leading to reduced anxiety among academic customers [13][66] - Biotech funding has improved from a decline of 30% to a decline of 13%, indicating a potential stabilization in the biotech market [16][22] Company Strategy and Development Direction - The company is focusing on its ProteinSimple and Spatial Biology franchises to drive growth, especially as the market stabilizes [26][29] - The company is optimistic about the long-term potential of its cell therapy business, despite short-term challenges due to the two large customers [90][94] - The company is leveraging its strong customer relationships and grant programs to maintain interest in cell therapy, indicating a strategic focus on early-stage development support [92] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the near-term outlook, noting that while challenges remain, there are signs of stabilization in key markets [11][13] - The company expects to see improvements in the biotech market, but anticipates that significant revenue contributions from this sector may not materialize until fiscal year 2027 [22][57] - Management highlighted the importance of upcoming FDA approvals and commercialization timelines for the two large customers, which could significantly impact future revenue [49][50] Other Important Information - The company has a diverse customer base, with 700 customers, and is actively seeking to expand its market presence despite current challenges [91] - The company is experiencing a high level of interest in its instruments, indicating potential for future growth as capital expenditures begin to recover [71] Q&A Session Summary Question: What is the impact of the two large customers on the business? - The two large customers accounted for 35%-40% of GMP revenue at their peak, and their absence is expected to impact revenue for the remainder of the fiscal year [41][52] Question: How does the company view the future of the cell therapy market? - Management believes the quality of new clinical trials is improving, and despite current funding challenges, interest in cell therapy remains high [90][92] Question: What are the expectations for the diagnostics business moving forward? - The diagnostics business is expected to continue performing well, with a more even revenue distribution anticipated throughout the year [30][31]

Financial Data and Key Metrics Changes - The company ended Q1 with a -1% growth, primarily impacted by two large cell therapy customers who did not purchase materials, contributing approximately 200 basis points of headwind [6][8] - Adjusted for these customers, the growth rate for the rest of the company was +1% [25] - The company anticipates a similar overall growth rate for Q2, projecting a decline of -1% but an improvement to +3% when excluding the impact of the two customers [25][26] Business Line Data and Key Metrics Changes - The diagnostics business grew mid-single digits in Q1, building on a mid-teen growth from the previous year, indicating a strong performance despite lumpiness in customer purchasing patterns [30] - The ProteinSimple franchise has consistently outperformed, with no down quarters and double-digit growth in most recent quarters, indicating strong demand for its consumables [26][68] - The Spatial Biology segment experienced a flat performance in Q1 after a down quarter in Q4, but bookings increased double-digit, suggesting a recovery in interest [27][75] Market Data and Key Metrics Changes - The Pharma market, which constitutes 30% of the company's revenue, has shown resilience with double-digit growth returning after a brief slowdown due to regulatory concerns [12][61] - Academic market funding has stabilized, with NIH budget expectations now flat, improving customer sentiment and reducing anxiety [13][66] - Biotech funding has improved from a -30% decline to -13%, indicating a potential recovery in spending [16][22] Company Strategy and Development Direction - The company is focusing on its ProteinSimple and Spatial Biology franchises to drive growth in a stabilizing market, leveraging historical performance to navigate current challenges [26][29] - The company is optimistic about the long-term potential of its cell therapy business, despite short-term headwinds from key customers [89][92] - The strategy includes maintaining strong relationships with existing customers while exploring new opportunities in the biotech space [54][94] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the near-term outlook, noting that while challenges remain, there are signs of stabilization in key markets [11][13] - The company expects to see a gradual recovery in the biotech sector, with funding translating into spending over the next few quarters [57] - Management highlighted the importance of upcoming FDA approvals and commercialization timelines for key customers, which could significantly impact future revenue [49][50] Other Important Information - The company has seen a significant increase in its customer base, growing from 550 to 700 customers, indicating strong interest in its products [92] - The company is actively engaging in grant programs to support early-stage cell therapy developments, which could lead to long-term customer loyalty [93] Q&A Session Summary Question: What is the impact of the two large customers on the business? - The two customers accounted for 35%-40% of GMP revenue at their peak, and their absence will significantly impact revenue for the remainder of the year [41][52] Question: What is the expected timeline for commercialization of the therapies from these customers? - Management anticipates a timeline of 18 months to three years for commercialization following phase III results, with a base case of fiscal year 2028 for potential revenue [49][50] Question: How does the company view the current state of the cell therapy market? - Management believes the quality of new clinical trials is improving despite a slowdown in the rate of growth, indicating a healthy future for the sector [92]

Financial Data and Key Metrics Changes - The company ended Q1 with a negative growth of 1%, but excluding two large cell therapy customers, the growth for the rest of the business was approximately 1% [6][8] - The company anticipates a similar overall growth rate for Q2, projecting a decline of about 1% but an improvement to 3% when excluding the impact of the two customers [25][30] Business Line Data and Key Metrics Changes - The diagnostics business grew mid-single digits in Q1, building on a mid-teen growth from the previous year, indicating a strong performance despite fluctuations [30] - The ProteinSimple franchise has consistently outperformed, with no down quarters and double-digit growth in recent periods, suggesting resilience in a challenging market [26][70] - The Spatial Biology segment experienced a flat performance in Q1 after a down quarter, but bookings increased double-digit, indicating potential for recovery [27][75] Market Data and Key Metrics Changes - The pharmaceutical market, which constitutes 30% of revenue, has shown recovery with double-digit growth in recent quarters, alleviating previous concerns about regulatory pressures [12][13] - Academic market conditions have stabilized, with expectations of a flat NIH budget, improving sentiment among academic customers [14][66] - Biotech funding has improved, with funding levels increasing from a decline of 30% to a decline of 13%, suggesting a potential recovery in spending [17][22] Company Strategy and Development Direction - The company is focusing on its ProteinSimple and Spatial franchises to drive growth, especially as market conditions stabilize [26][75] - The strategy includes leveraging the strong demand for consumables and reagents associated with their instruments, which are expected to enhance margins over time [77][80] - The company is optimistic about the long-term potential of its cell therapy business, despite short-term challenges, due to the high quality of clinical trials being conducted [92][94] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the near-term outlook, noting that while challenges remain, there are signs of stabilization in key markets [12][14] - The company anticipates that improvements in funding and market conditions will begin to reflect in financial results by the second half of fiscal year 2026 [22][58] - Management highlighted the importance of maintaining strong relationships with customers and adapting to their needs as market conditions evolve [43][59] Other Important Information - The two large customers in the cell therapy space accounted for as much as 35%-40% of GMP revenue at their peak, but their absence is expected to impact revenue significantly in the near term [41][90] - The company has a diverse customer base, with 698 other customers, and is actively seeking to expand its reach in the cell therapy market through grant programs [94][96] Q&A Session Summary Question: What is the impact of the two large customers on revenue? - The two customers have significantly influenced revenue, making up a large portion of GMP revenue, and their absence is expected to reduce business temporarily [41][90] Question: How does the company view the recovery in the biotech market? - The company sees a lag of 2-3 quarters before funding translates into spending, but is optimistic about a recovery in fiscal year 2027 [58] Question: What are the expectations for the diagnostics business? - The diagnostics business is expected to continue performing well, with a more even revenue stream anticipated throughout the year [30][31] Question: How is the company addressing margin progression? - Management expects margin expansion to be consistent with revenue growth, projecting at least a 100 basis point improvement for the year [97]

山东省护理学会秘书长郭明兴在开幕式讲话中指出，护理工作是医疗卫生事业的重要基石，而脐带血采 集护理作为产科专科护理的关键领域，其技术规范性直接关系到生命资源的质量与临床价值的发挥。郭 明兴强调，本次大会搭建的高规格学术交流平台，既是技术经验的共享阵地，更是创新理念的碰撞舞 台，将推动全省护理人员在技术能力、服务理念上实现双重提升，为脐带血医学事业发展提供坚实的护 理保障。 临床一线的实践经验是推动技术发展的核心动力。山东第一医科大学第一附属医院妇儿科大科护士长、 山东省护理学会脐带血采集应用专委会主任委员王君芝结合产科护理经验提出了深刻见解。她指出，脐 带血作为富含造血干细胞的宝贵资源，其医学价值正从血液疾病治疗不断拓展至免疫治疗、神经修复等 再生医学领域，而规范的采集工作正是激活这份价值的关键环节。作为主任委员，她表示将带领专委会 搭建更广阔的学术交流桥梁，编织更严密的培训网络，推动先进技术与人文关怀在产科护理中深度融 合，让每一份脐带血都能得到最好守护。 初冬的泉城暖意融融，生命科学的脉动强劲有力。2025年11月29日，由山东省护理学会主办，山东省护 理学会脐带血采集应用专业委员会承办，山东第一医科大学 ...

Core Viewpoint - Longeveron Inc. has received a Canadian patent for its proprietary mesenchymal stem cell therapy, laromestrocel (LOMECEL-B), aimed at treating aging-related frailty and non-ischemic dilated cardiomyopathy, which positions the company favorably in the biotechnology sector focused on regenerative medicine [1][2][8] Company Overview - Longeveron Inc. is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs, with its lead product being laromestrocel, an allogeneic mesenchymal stem cell therapy derived from the bone marrow of young, healthy adult donors [7] - The company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and pediatric dilated cardiomyopathy (DCM) [7] Patent Details - The Canadian Patent No. 3043594 grants Longeveron rights to administer laromestrocel for treating aging-related frailty and non-ischemic dilated cardiomyopathy until 2037 [2][8] - The patent covers methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells to patients with aging-related frailty and NIDCM [8] Clinical Research - Longeveron has conducted Phase 1 and 2 studies demonstrating improvements in physical functioning and the six-minute walk test for aging-related frailty using laromestrocel [4][8] - Non-ischemic dilated cardiomyopathy is a progressive disorder with no current cure, and laromestrocel has shown potential in altering immunologic markers associated with chronic inflammation [5][8] Mechanism of Action - Laromestrocel is believed to have multiple mechanisms of action, including anti-inflammatory and pro-vascular regenerative responses, which may have broad applications for various rare and aging-related diseases [6][7]

撰文丨王聪 编辑丨王多鱼 排版丨水成文 该研究首次发现，在人类和小鼠的多能干细胞共培养中，通过" 隧道纳米管 " （ Tunneling Nanotube， TNT ） 结构进行的 跨物种 RNA 交换 ， 可激活小鼠细胞的 RNA 先天 免疫通路，进而通过"细胞竞争"清 除人类细胞。 该研究进一步证实 ，敲除通路关键蛋白 MAVS 能够削弱小鼠细胞竞争力，在不修饰人类细胞的情况下，显 著提升人类多能干细胞在小鼠胚胎中的存活率和嵌合率。 这一发现揭示了物种间屏障和细胞竞争的新机 制， 证明了靶向抑制宿主免疫通路是提高动物体内的人类细胞嵌合率的有效策略，为再生医学提供了更具 安全性的"宿主改造"新范式。 利用 人类多能干细胞 （hPSC） 创建 跨物种嵌合体 ， 为模拟人类发育和生成供体器官提供了前景广阔的 策略，然而，人类细胞在其他物种中的整合效率低下，这也成为 创建 跨物种嵌合体面临的 主要障碍。 目前改善人源细胞嵌合率的努力，多集中于对供体 hPSC 进行基因改造，而对宿主进行调控的研究仍然不 足。 2025 年 11 月 24 日，德克萨斯大学西南医学中心 吴军 团队与基因组多维解析技术全国重点实验室/ ...